Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson’s disease

被引：0
作者：
Naoto Kadoguchi
Shinji Okabe
Yukio Yamamura
Misaki Shono
Tatsuya Fukano
Akie Tanabe
Hironori Yokoyama
Jiro Kasahara
机构：
[1] The University of Tokushima,Department of Neurobiology and Therapeutics, Institute of Health Bioscience, Graduate School and Faculty of Pharmaceutical Sciences
来源：
BMC Neuroscience | / 15卷
关键词：
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP); Parkinson’s disease; Mirtazapine; Noradrenergic and specific serotonergic antidepressant (NaSSA); Serotonin (5-hydroxytryptamine, 5-HT); Dopamine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 191 条
[1]  
Samii A(2004)Parkinson's disease Lancet 363 1783-1793
[2]  
Nutt JG(1973)Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations J Neurol Sci 20 415-455
[3]  
Ransom B(1991)Parkinson’s disease: pathophysiology Lancet 337 1321-1324
[4]  
Bernheimer H(2002)Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology J Neurol 58 11-17
[5]  
Birkmayer W(2012)Clinical inquiry. Which drugs work best for early Parkinson's disease? J Fam Pract 61 106-108
[6]  
Hornykiewicz O(2001)Dyskinesia: ʟ-dopa-induced and tardive dyskinesia Clin Neuropharmacol 24 313-323
[7]  
Jellinger K(2012)Serotonergic action on dorsal striatal function Parkinsonism Relat Disord 18 129-131
[8]  
Seitelberger F(2012)Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease J Clin Neurosci 19 343-348
[9]  
Agid Y(2002)5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy Eur J Pharmacol 453 217-221
[10]  
Miyasaki JM(2003)Serotonergic involvement in haloperidol-induced catalepsy J Pharmacol Exp Ther 265 207-217
12345678910